Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 15/20 | 0.87 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558525 | 1.00 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4484373 | 1.00 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4484371 | 1.00 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4481080 | 0.94 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4481085 | 0.94 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4481090 | 0.94 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL9885103 | 0.93 | ABCB1 (1.00) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL9885702 | 0.93 | ABCB1 (1.00) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL9103699 | 0.92 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL9100176 | 0.92 | ABCB1 (0.87) | ABCB1STING1ALDH1A1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068503-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-03-10 | — | — | US | disclosed |
| US-9169230-B2 | (−)-Epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2015-10-27 | — | — | US | disclosed |
| US-20140213802-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2014-07-31 | — | — | US | disclosed |
| US-8710248-B2 | (−)-epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2014-04-29 | — | — | US | disclosed |
| US-20120232135-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2012-09-13 | — | — | US | disclosed |
| US-8193377-B2 | (−)-epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2012-06-05 | — | — | US | disclosed |
| US-7544816-B2 | (−)-Epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2009-06-09 | — | — | US | disclosed |
| EP-1778663-A4 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | UNIV HONG KONG POLYTECHNIC (CN) | 2008-08-06 | — | — | EP | disclosed |
| US-20080176931-A1 | e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2008-07-24 | — | — | US | disclosed |
| EP-1778663-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | The Hong Kong Polytechnic University (CN) | 2007-05-02 | — | — | EP | disclosed |
| US-20060041010-A1 | 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2006-02-23 | — | — | US | disclosed |
| WO-2006017981-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232135-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | PSMC1, PSME1, PSMB1 | ABCB1 2548/4885STING1 3254/4885ALDH1A1 2841/4885 |
| US-20060041010-A1 | 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | PSMB10, PSMC1, PSMD10 | ABCB1 916/4885STING1 3257/4885ALDH1A1 927/4885 |
| US-20160068503-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | PSMC1, PSME1, PSMB1 | ABCB1 2548/4885STING1 3254/4885ALDH1A1 2841/4885 |
| US-20140213802-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | PSMC1, PSME1, PSMB1 | ABCB1 2548/4885STING1 3254/4885ALDH1A1 2841/4885 |
| US-20080176931-A1 | e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | UBE2G2, C9, BAP1 | ABCB1 1438/4885STING1 3187/4885ALDH1A1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.